Shanghai Henlius Biotech’s Zercepac (trastuzumab) biosimilar, which has been licensed to Accord Healthcare, has become “the first China-developed monoclonal antibody biosimilar that has successfully entered the EU market,” the Chinese firm said, following formal approval from the European Commission.
Accord Adds To Crowded EU Trastuzumab Market
First China-Developed mAb To Launch In EU
Shanghai Henlius Biotech is to make history with the first China-developed monoclonal antibody biosimilar in Europe, the firm’s Zercepac (trastuzumab) biosimilar that has been licensed to Accord Healthcare.
